May 2026
MDMA
What May 2026's 12 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
Research published in May 2026 on MDMA shows that while MDMA-assisted therapy produces moderate-to-large reductions in psychopathology compared to controls, especially for trauma, blinding in trials is often insufficient. MDMA reliably enhances subjective social experience and emotional empathy but does not consistently translate into observable prosocial behavior, and its use carries risks including oxidative stress, neuroinflammation, and severe hyponatremia, particularly in unsupervised settings. The evidence is limited by high heterogeneity, small samples, and a lack of long-term safety data.
Confidence in the evidence
Moderate- The meta-analysis (article 27858) includes 8 controlled trials with 295 participants, showing a moderate-to-large effect but with high heterogeneity (I²=76%).
- The systematic review of social functioning (article 28578) covers 76 studies, providing consistent evidence for subjective effects but mixed behavioral results.
- Blinding integrity is a major concern (article 27762), with functional unblinding in MDMA trials, reducing confidence in effect estimates.
- Safety data are limited to preclinical models (articles 28507, 28509) and a single case report (article 28502), with no large-scale clinical safety trials.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Antibiotic-induced Microbiome Depletion Selectively Reduces Baseline Hypothalamic Oxytocin Signaling without Affecting MDMA-induced Oxytocin Response in Rats. 2026 | preclinical | — | No effect | Antibiotic-induced microbiome depletion reduced baseline central oxytocin but did not affect MDMA-induced oxytocin responses in rats. |
| The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression 2026 | narrative review | — | Unclear | The review notes that peripheral 5-HT2B receptor agonism is linked to valvular heart disease, with limited data for MDMA, and that cumulative exposure risks remain insufficiently characterized. |
| Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers. 2026 | RCT | 120 | Opposes | Blinding was insufficient in a trial comparing psilocybin, MDMA, and methylphenidate, with MDMA showing moderate levels of functional unblinding. |
| Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms. 2026 | cross-sectional | 140 | Mixed | Chronic MDMA use was linked to selective activation of the OH-kynurenine metabolic branch in tryptophan pathways, with metabolite changes associated with psychopathology severity. |
| Reply: The consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors. 2026 | reply/commentary | — | Unclear | The reply argues that consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors. |
| Psychedelic Use and Missed Needed Mental Health Treatment: Gender Differences in Unmet Perceived Need for Care 2026 | observational | — | Mixed | Lifetime psychedelic use was not independently associated with lower odds of missing needed mental health treatment, but MDMA showed a moderating effect for women in buffering the link between distress and missed care. |
| Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study. 2026 | Delphi study | 12 | Unclear | A Delphi process developed the M-SET, a 165-item tool to systematically assess side effects of MDMA-assisted psychotherapy. |
| R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential. 2026 | preclinical | — | Supports | R-MDDMA, a methylated analogue of MDMA, did not activate 5-HT2B receptors or induce serotonin efflux but still promoted structural neuroplasticity and produced antidepressant-like effects in rats. |
| Glutathione as a Potential Neuroprotectant Against MDMA-Induced Oxidative Stress, Neuroinflammation, and Apoptosis in the Rat Brain. 2026 | preclinical | 60 | Opposes | MDMA administration in rats led to oxidative stress, neuroinflammation, and apoptosis, with glutathione showing potential neuroprotective effects. |
| MDMA-Assisted Therapy Randomized Controlled Trial Incremental Effects Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 295 | Supports | MDMA-assisted therapy showed a significant moderate-to-large incremental reduction in psychopathology (g=1.03) compared to controls, with larger effects for trauma (g=1.46) and non-significant effects for depression (g=0.51). |
| A Systematic Review of MDMA’s Effects on Social Functioning in Placebo-Controlled Trials 2026 | systematic review | — | Mixed | MDMA reliably enhanced subjective social experience and emotional empathy but did not consistently translate into observable prosocial behavior; the most robust social effect was reduced processing of social threat. |
| Severe Hyponatremic Encephalopathy Induced by Unsupervised "Therapeutic" 3,4-Methylenedioxymethamphetamine Use in a 55-Year-Old Woman: A Diagnostic Pitfall. 2026 | case report | 1 | Opposes | Unsupervised 'therapeutic' MDMA use led to severe hyponatremic encephalopathy in a 55-year-old woman, highlighting risks in older populations and non-recreational settings. |
Antibiotic-induced microbiome depletion reduced baseline central oxytocin but did not affect MDMA-induced oxytocin responses in rats.
preclinical
The review notes that peripheral 5-HT2B receptor agonism is linked to valvular heart disease, with limited data for MDMA, and that cumulative exposure risks remain insufficiently characterized.
narrative review
Blinding was insufficient in a trial comparing psilocybin, MDMA, and methylphenidate, with MDMA showing moderate levels of functional unblinding.
RCT · Sample size: 120
Chronic MDMA use was linked to selective activation of the OH-kynurenine metabolic branch in tryptophan pathways, with metabolite changes associated with psychopathology severity.
cross-sectional · Sample size: 140
The reply argues that consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors.
reply/commentary
Lifetime psychedelic use was not independently associated with lower odds of missing needed mental health treatment, but MDMA showed a moderating effect for women in buffering the link between distress and missed care.
observational
A Delphi process developed the M-SET, a 165-item tool to systematically assess side effects of MDMA-assisted psychotherapy.
Delphi study · Sample size: 12
R-MDDMA, a methylated analogue of MDMA, did not activate 5-HT2B receptors or induce serotonin efflux but still promoted structural neuroplasticity and produced antidepressant-like effects in rats.
preclinical
MDMA administration in rats led to oxidative stress, neuroinflammation, and apoptosis, with glutathione showing potential neuroprotective effects.
preclinical · Sample size: 60
MDMA-assisted therapy showed a significant moderate-to-large incremental reduction in psychopathology (g=1.03) compared to controls, with larger effects for trauma (g=1.46) and non-significant effects for depression (g=0.51).
systematic review and meta-analysis · Sample size: 295
MDMA reliably enhanced subjective social experience and emotional empathy but did not consistently translate into observable prosocial behavior; the most robust social effect was reduced processing of social threat.
systematic review
Unsupervised 'therapeutic' MDMA use led to severe hyponatremic encephalopathy in a 55-year-old woman, highlighting risks in older populations and non-recreational settings.
case report · Sample size: 1
Points of agreement
- MDMA-assisted therapy shows moderate-to-large effects on reducing psychopathology, particularly trauma symptoms.
- MDMA reliably enhances subjective social experience and emotional empathy.
- MDMA use is associated with risks including oxidative stress, neuroinflammation, and potential cardiac effects via 5-HT2B receptor activation.
- Blinding in MDMA trials is often insufficient, complicating interpretation of efficacy.
Conflicts
- The meta-analysis (article 27858) found a significant effect for trauma but a non-significant effect for depression, while other studies suggest broader therapeutic potential.
- Subjective prosocial effects of MDMA are consistent, but behavioral measures of prosociality are inconsistent and context-dependent (article 28578).
- Preclinical studies show MDMA-induced oxytocin responses are preserved despite microbiome depletion (article 28509), but clinical implications are unclear.
Gaps
- Long-term safety and cumulative exposure risks of MDMA, especially regarding cardiac effects, are insufficiently characterized.
- Durability of therapeutic effects beyond the trial period is not addressed.
- Blinding integrity remains a major methodological gap in psychedelic trials.
- Effects in diverse populations (e.g., older adults, women) are understudied, with only one case report on severe hyponatremia in an older woman.
- The role of gut microbiota in MDMA's effects in humans is unexplored.